Abstract:The clinical effectiveness of adrenocorticotropin in inducing remission of steroid-resistant nephrotic syndrome points to a steroidogenic-independent anti-proteinuric activity of melanocortins. However, which melanocortin receptors (MCR) convey this beneficial effect and if systemic or podocyte-specific mechanisms are involved remain uncertain. In vivo, wild-type (WT) mice developed heavy proteinuria and kidney dysfunction following Adriamycin insult, concomitant with focal segmental glomerulosclerosis (FSGS) and podocytopathy, marked by loss of podocin and synaptopodin, podocytopenia and extensive foot process effacement on electron microscopy. All these pathologic findings were prominently attenuated by NDP-MSH, a potent non-steroidogenic pan-MCR agonist. Surprisingly, MC1R deficiency in MC1R-null mice barely affected the severity of Adriamycin-elicited injury. Moreover, the beneficial effect of NDP-MSH was completely preserved in MC1R-null mice, suggesting that MC1R is likely non-essential for the protective action. A direct podocyte effect seems to contribute to the beneficial effect of NDP-MSH, because Adriamycin-inflicted cytopathic signs in primary podocytes prepared from WT mice were all mitigated by NDP-MSH, including apoptosis, loss of podocyte markers, de novo expression of the podocyte injury marker desmin, actin cytoskeleton derangement and podocyte hypermotility. Consistent with in vivo findings, the podoprotective activity of NDP-MSH was fully preserved in MC1R-null podocytes. Mechanistically, MC1R expression was predominantly distributed to glomerular endothelial cells in glomeruli but negligibly noted in podocytes in vivo and in vitro, suggesting that MC1R signaling is unlikely involved in direct podocyte protection. Ergo, melanocortin therapy protects against podocyte injury and ameliorates proteinuria and glomerulopathy in experimental FSGS, at least in part, via a podocyte-specific non-MC1R-mediated melanocortinergic signaling.

MCC Regulator of WNT Signaling Pathway (MCC) is a Podocyte Essential Gene

[New Insight in Pathogenesis of Podocyte Disfunction in Minimal Change Disease].

Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease

Genome-wide identification of genes essential for podocyte cytoskeletons based on single-cell RNA sequencing.

CCDC92 promotes podocyte injury by regulating PA28α/ABCA1/cholesterol efflux axis in type 2 diabetic mice

GEMC1-MCIDAS transcriptional program regulates multiciliogenesis in the choroid plexus and acts as a barrier to tumorigenesis

Melanocortin Therapy Ameliorates Podocytopathy and Proteinuria in Experimental Focal Segmental Glomerulosclerosis Involving a Podocyte Specific Non-Mc1r-mediated Melanocortinergic Signaling.

Pharmacological Targeting of GSK3β Confers Protection Against Podocytopathy and Proteinuria by Desensitizing Mitochondrial Permeability Transition

Hyperactivation of p53 contributes to mitotic catastrophe in podocytes through regulation of the Wee1/CDK1/cyclin B1 axis

Weighted Gene Correlation Network Analysis (WGCNA) Detected Loss of MAGI2 Promotes Chronic Kidney Disease (CKD) by Podocyte Damage.

Downregulation of CD2‐associated Protein Impaired the Physiological Functions of Podocytes

MicroRNA-466o-3p mediates β-catenin-induced podocyte injury by targeting Wilms tumor 1

miR-135 family members mediate podocyte injury through the activation of Wnt/β-catenin signaling

Profilin1 is required for prevention of mitotic catastrophe in murine and human glomerular diseases

Inhibition of RAC Attenuates Adriamycin-induced Podocyte Injury

Wnt / β-catenin pathway involved in podocyte injury is regulated by UCH-L 1

Metadherin orchestrates PKA and PKM2 to activate β-catenin signaling in podocytes during proteinuric chronic kidney disease

Down-regulation of Wt1 Activates Wnt/β-catenin Signaling Through Modulating Endocytic Route of LRP6 in Podocyte Dysfunction in Vitro.

KIBRA upregulation increases susceptibility to podocyte injury and glomerular disease progression

mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice.

CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease